中国慢性阻塞性肺病人口查的成本效益:基于世卫组织合作中心发起的"享受呼吸计划"的个人数据
Tiantian Zhang1,2, Jiahuan Ai1, Ke Huang3
1College of Pharmacy/Southern Institute of Pharmacoeconomics and Health Technology Assessment, Jinan University, Guangzhou, China.
BMC public health
|April 24, 2025
概括
享受呼吸计划用于慢性阻塞性肺病 (COPD) 查在中国可能具有成本效益. 这个全国性的计划提供了显著的健康益处,使得早期COPD检测成为一个有价值的公共卫生战略.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一个重大的全球健康挑战.
- 早期发现和诊断COPD对于减轻公共卫生负担至关重要.
- 享受呼吸计划 (EBP) 已显示出临床益处,但其成本效益尚不清楚.
研究的目的:
- 评估EBP在中国COPD查方面的成本效益.
- 从中国医疗保健的角度来看,比较EBP与无查方法.
主要方法:
- 一个终身马尔科夫模型被用于成本效益分析.
- 来自EBP的患者级数据 (治疗率,药物成本,过渡概率) 被纳入.
- 外部出版的文献提供了额外的参数数据.
主要成果:
- 对COPD查的EBP可能具有成本效益,增量成本为118美元,获得0.021个质量调整寿命年 (QALY).
- 增量成本效益比 (ICER) 为5,679美元/QALY,远低于中国2022年的人均GDP支付意愿门 (11,814美元).
- 敏感性和子组分析证实了结果的稳定性,并突出了不同人群健康益处的差异.
结论:
- 通过EBP在中国每年进行两步COPD人口查似乎可能具有成本效益.
- 尽管存在固有的不确定性,该计划仍需要进一步大规模实施.
- 优化选频率和合规性可以进一步提高成本效益.
更多相关视频
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.4K
Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
Lung Capacity
47.8K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
47.8K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
122
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
122
Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K


